

A LEAP FORWARD



IN AAV RESEARCH & GENE THERAPY


ANTIBODIES

Over 30 antibodies
Available for AAV serotypes 1, 2, 4, 5, 6, 8, 9
Capsid-specific antibodies
AAV replicase antibodies

ELISAs

Reliable AAV titer quantification
Specific recognition of intact AAV particles
Available for AAV serotypes 1, 2, 5, 6, 8, 9
Validated assays for standardized approaches





Antigen	Product Specifications	Cat. No.
AAV1	mouse mAb, clone ADK1a	610150
AAV2	mouse mAb, clone A20	61055
AAV4	mouse mAb, clone ADK4	610147
AAV5	mouse mAb, clone ADK5b	610149
AAV5	mouse mAb, clone ADK5a	610148
AAV5	rabbit polyclonal Ab	610137
AAV6	mouse mAb, clone ADK6	651159
AAV8	mouse mAb, clone ADK8	651160
AAV8/9	mouse mAb, clone	651161
AAV9	mouse mAb, clone ADK9	651162
VP1	mouse mAb, clone A1	61056
VP1/VP2	mouse mAb, clone A69	61057
VP1/VP2/VP3	mouse mAb, clone B1	61058
VP1/VP2/VP3	rabbit polyclonal Ab	61084
AAV-Rep	mouse mAb, clone 259.5	61071
AAV-Rep	mouse mAb, clone 226.7	65172
AAV-Rep	mouse mAb, clone 303.9	61069
AAV-Rep	mouse mAb, clone 76.3	61073



AAV ANTIBODIES FOR EVERY APPLICATION

Anti-AAV antibodies are suitable for the characterization of different stages of adeno-associated virus (AAV) infection and are very useful for the analysis of the AAV assembly process. The antibodies specifically recognize conformational epitopes in assembled capsids of different AAV serotypes. Hence, they react with empty and full capsids as well as with intact AAV particles.

Viral capsid protein antibodies (VP) exclusively recognize AAV capsid proteins and are useful for immunolocalization studies of AAV capsid formation or immunoprecipitation of viral capsid proteins.

Anti-AAV replicase antibodies (Rep) react with selected replicase (Rep) proteins in human AAV-infected cells. Applications include immunolocalization or immunoblotting studies to investigate the correlation between Rep expression and the course of an infection.



STANDARDIZED RESEARCH WITH AAV TITRATION ELISAs

AAV vectors are powerful tools in gene therapy research and development. Recombinant AAV vectors (rAAV) corresponding to the different viral serotypes have been successfully used as universal gene shuttle in human cells. The advantages of AAV transduction include a long-term gene expression with low immunogenicity and no serious vector-related adverse effects in several clinical trials.¹

The increasing interest in rAAV for clinical applications demands a dependable and reproducible quantification of accurate rAAV titers to ensure a safe and reliable gene transfer. In view of this scientific and clinical significance, PROGEN has established a line of AAV quantification ELISAs for different AAV serotypes (1, 2, 5, 6, 8, and 9), utilizing its portfolio of capsid-specific AAV antibodies. The assays for the determination of rAAV2 and rAAV8 titers have been validated in international studies^{2, 3} and have been classified as superior method for a reliable, standardized rAAV particle titer quantification.



Product	Cat. No.
AAV1	PRAAV1
AAV2	PRATV
AAV5	PRAAV5
AAV6	PRAAV6
AAV8	PRAAV8
AAV9	PRAAV9

¹ Naldini L., 2015, Nature 526:351–360 (Review)
² Ayuso E. et al., 2014, Human Gene Therapy 25:977–987
³ Lock M. et al., 2010, Human Gene Therapy 21:1273–1285

